Author

X.-C. Chen

Primary ORCID profile (0009-0002-1363-1672 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

X.-C. CheniD1 paper · Case Western Reserve University

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

A. E. Shchekotikhin· 1 shared A. Islam· 1 shared A. S. Tikhomirov· 1 shared C. Sun· 1 shared C.-W. Ke· 1 shared C.-W. Wang· 1 shared C.-W. Weng· 1 shared C.-Y. Chen· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. E. Shchekotikhin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Water-soluble 4-(dimethylaminomethyl)heliomycin exerts greater antitumor effects than parental heliomycin by targeting the tNOX-SIRT1 axis and apoptosis in oral cancer cells

A. Islam, Y.-C. Chang, X.-C. Chen, C.-W. Weng, C.-Y. Chen, C.-W. Wang, M.-K. Chen, A. S. Tikhomirov, A. E. Shchekotikhin, P. J. Chueh

This study identifies 4-dmH, a water-soluble heliomycin derivative, as more effective than parental heliomycin in oral cancer by targeting the tNOX-SIRT1 axis and inducing apoptosis.

bioRxiv · Mar 29, 2023Cell Biology

Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate

Y.-F. Kang, C. Sun, Z. Zhuang, R.-Y. Yuan, Q.-B. Zheng, P.-P. Zhou, J.-P. Li, X.-C. Chen, X. Zhang, X.-H. Yu, X.-W. Kong, Q.-Y. Zhu, M. Xu, N.-S. Zhong, Y.-X. Zeng, , M.-S. Zeng

This study designs and tests RBD-conjugated nanoparticle vaccines against SARS-CoV-2, showing enhanced neutralizing activity compared to monomeric RBD.

bioRxiv · Nov 3, 2020 · PreprintMicrobiology